AUROBINDO PHARMA |
Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 1.154 INR | +0,15 % |
|
+7,18 % | +6,41 % |
Kurzporträt
- Generika: für die Behandlung von neurologischen, kardiovaskulären, viralen, gastroenterologischen, ophthalmologischen und chronischen Krankheiten;
- pharmazeutische Wirkstoffe.
Ende März 2018 betrieb die Gruppe 23 Produktionsstandorte in Indien (19), den Vereinigten Staaten (3) und Brasilien.
Der Nettoumsatz verteilt sich geografisch wie folgt: Indien (12%), die Vereinigten Staaten (46,5%), Europa (31,2%) und Sonstige (10,3%).
Mitarbeiterzahl: 23 451
Umsatz nach Geschäftsbereich
| INR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Generic Pharmaceuticals and Related Services
97,0
%
| 231 243 | 98,6 % | 241 044 | 97,0 % | +4,24 % |
Services
2,1
%
| 2 422 | 1,0 % | 5 128 | 2,1 % | +111,67 % |
Government Incentive Schemes
0,9
%
| 314 | 0,1 % | 2 176 | 0,9 % | +593,81 % |
Scrap
0,1
%
| 197 | 0,1 % | 207 | 0,1 % | +5,03 % |
Umsatz je Region
| INR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
45,2
%
| 105 208 | 44,9 % | 112 421 | 45,2 % | +6,86 % |
Europe
29,1
%
| 78 813 | 33,6 % | 72 430 | 29,1 % | -8,10 % |
Rest of the World
14,6
%
| 23 835 | 10,2 % | 36 222 | 14,6 % | +51,97 % |
India
11,1
%
| 26 700 | 11,4 % | 27 482 | 11,1 % | +2,93 % |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
| Founder | 66 | 26.12.86 | |
| Director of Finance/CFO | - | 01.01.13 | |
B. Adi Reddy
CMP | Compliance Officer | - | 01.06.16 |
| Director/Board Member | - | 01.01.16 | |
| Corporate Officer/Principal | 68 | 01.02.00 | |
| Corporate Officer/Principal | 59 | 01.02.16 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
| Founder | 66 | 26.12.86 | |
| Founder | 66 | 26.12.86 | |
| Director/Board Member | 64 | 27.05.03 | |
| Director/Board Member | 39 | 27.09.07 | |
| Director/Board Member | 67 | 09.02.23 | |
| Director/Board Member | 64 | 10.02. | |
Savita Mahajan
BRD | Director/Board Member | 65 | 16.12.17 |
| Director/Board Member | 52 | 05.11.20 | |
| Director/Board Member | - | 01.01.16 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 1 | 585 938 609 | 280 869 458 ( 47,93 %) | 0 | 47,93 % |
Unternehmenskontakt
Aurobindo Pharma Ltd.
Plot No. 1, Hyderabad Knowledge City Raidurg Panmaktha, Galaxy
500032, Hyderabad
+91 40 6672 5000
http://www.aurobindo.com
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Auronext Pharma Pvt Ltd.
 Auronext Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Aurobindo Pharma Ltd., Auronext Pharma Pvt Ltd. is a pharmaceutical company founded in 2009. The private company is based in Hyderabad, India. The Indian company manufactures and supplies pharmaceutical products. |
Pharmaceuticals: Major
|
APL Healthcare Ltd.
 APL Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Part of Aurobindo Pharma Ltd., APL Healthcare Ltd. is a fully integrated pharmaceutical company based in Hyderabad, IN. The private company also has a strong focus on sustainability and social responsibility, with initiatives in place to ensure compliance with social accountability standards, human rights policies, and progressive health and safety practices. APL Healthcare is dedicated to providing access to healthcare and has programs in place to support this goal. The Indian company offers a range of products and services including formulations, custom synthesis, peptides, and R & D. APL Healthcare is committed to quality and safety, with manufacturing facilities approved by various regulatory bodies including the US FDA, UK MHRA, TGA, MCC-SA, EMA, and ANVISA. |
Pharmaceuticals: Major
|
Silicon Life Sciences Pvt Ltd.
 Silicon Life Sciences Pvt Ltd. Medical SpecialtiesHealth Technology Part of Aurobindo Pharma Ltd., Silicon Life Sciences Pvt Ltd. is an Indian company that manufactures non sterile penems. The private company is based in Parawada, India. The company was founded in 2008. Silicon Life Sciences was acquired by Aurobindo Pharma Ltd. on August 10, 2013 for $1.07 million. |
Medical Specialties
|
Eugia Pharma Specialities Ltd.
 Eugia Pharma Specialities Ltd. Miscellaneous Commercial ServicesCommercial Services Eugia Pharma Specialities Ltd. develops, manufactures and markets hormonal and oncology generic formulations. The company is headquartered in Hyderabad, India. |
Miscellaneous Commercial Services
|
Auro Peptides Ltd.
 Auro Peptides Ltd. Chemicals: SpecialtyProcess Industries Part of Aurobindo Pharma Ltd., Auro Peptides Ltd. is an Indian company that manufactures peptides. The private company is based in Hyderabad, India. |
Chemicals: Specialty
|
Apitoria Pharma Pvt Ltd.
| |
Curateq Biologics Pvt Ltd.
| |
Aurobindo Pharma Foundation
|
Investment Trusts/Mutual Funds
|
Lyfius Pharma Pvt Ltd.
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| +6,41 % | 8,1 Mrd. | |
| +34,00 % | 704 Mrd. | |
| +29,29 % | 577 Mrd. | |
| -7,75 % | 348 Mrd. | |
| +18,53 % | 327 Mrd. | |
| +4,95 % | 288 Mrd. | |
| +13,79 % | 234 Mrd. | |
| +4,93 % | 198 Mrd. | |
| -9,78 % | 194 Mrd. | |
| -4,89 % | 147 Mrd. |
- Börse
- Aktien
- A1H7U6 Aktie
- Unternehmen Aurobindo Pharma
